Azitra Inc (AZTR) is a publicly traded Healthcare sector company. As of May 21, 2026, AZTR trades at $0.20 with a market cap of $3.08M and a P/E ratio of -0.09. AZTR moved +3.68% today. Year to date, AZTR is -30.56%; over the trailing twelve months it is -89.97%. Its 52-week range spans $0.10 to $4.33. Analyst consensus is buy with an average price target of $1.00. Rallies surfaces AZTR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in AZTR news today?
Azitra Raises $10.5 M, Adds MD Anderson Site, Secures ATR-12 Patent: Azitra added MD Anderson Cancer Center as a site for its Phase 1/2 ATR-04 EGFRi rash trial and launched proprietary filaggrin protein and peptide programs for cosmetic markets. The company secured a U.S. patent for ATR-12, raised $10.5 million in private placement financing (with $20.9 million in warrant proceeds), and held $10.1 million in cash.
Azitra Raises $10.5 M, Adds MD Anderson Site, Secures ATR-12 Patent: Azitra added MD Anderson Cancer Center as a site for its Phase 1/2 ATR-04 EGFRi rash trial and launched proprietary filaggrin protein and peptide programs for cosmetic markets. The company secured a U.S. patent for ATR-12, raised $10.5 million in private placement financing (with $20.9 million in warrant proceeds), and held $10.1 million in cash.
Does Rallies summarize AZTR news?
Yes. Rallies summarizes AZTR news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is AZTR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AZTR. It does not provide personalized investment advice.
